Evidence map›Paper›PMID 34285268›Full record

ArticleScientific reports2021

Synergistic effect of cold atmospheric pressure plasma and free or liposomal doxorubicin on melanoma cells.

Konstantina Pefani-Antimisiari, Dimitrios K Athanasopoulos, Antonia Marazioti, Kyriakos Sklias, Maria Rodi, Anne-Lise de Lastic, Athanasia Mouzaki, Panagiotis Svarnas, Sophia G Antimisiaris

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Konstantina Pefani-Antimisiari *Pharmaceutical Technology Laboratory, Department of Pharmacy, University of Patras, 26504, Rion, Greece.
Dimitrios K Athanasopoulos *High Voltage Laboratory, Department of Electrical and Computer Engineering, University of Patras, 26504, Rion, Greece.
Antonia MaraziotiPharmaceutical Technology Laboratory, Department of Pharmacy, University of Patras, 26504, Rion, Greece. amarazioti@upatras.gr.
Kyriakos SkliasHigh Voltage Laboratory, Department of Electrical and Computer Engineering, University of Patras, 26504, Rion, Greece.
Maria RodiLaboratory of Immunohematology, Division of Hematology, Department of Internal Medicine, Medical School, University of Patras, 26500, Patras, Greece.
Anne-Lise de LasticLaboratory of Immunohematology, Division of Hematology, Department of Internal Medicine, Medical School, University of Patras, 26500, Patras, Greece.
Athanasia MouzakiLaboratory of Immunohematology, Division of Hematology, Department of Internal Medicine, Medical School, University of Patras, 26500, Patras, Greece.
Panagiotis SvarnasHigh Voltage Laboratory, Department of Electrical and Computer Engineering, University of Patras, 26504, Rion, Greece. svarnas@ece.upatras.gr.
Sophia G AntimisiarisPharmaceutical Technology Laboratory, Department of Pharmacy, University of Patras, 26504, Rion, Greece.
University of Patras · GRFORTH Institute of Chemical Engineering Sciences · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the present study was to investigate combined effects of cold atmospheric plasma (CAP) and the chemotherapeutic drug doxorubicin (DOX) on murine and human melanoma cells, and normal cells. In addition to free drug, the combination of CAP with a liposomal drug (DOX-LIP) was also studied for the first time. Thiazolyl blue tetrazolium bromide (MTT) and Trypan Blue exclusion assays were used to evaluate cell viability; the mechanism of cell death was evaluated by flow cytometry. Combined treatment effects on the clonogenic capability of melanoma cells, was also tested with soft agar colony formation assay. Furthermore the effect of CAP on the cellular uptake of DOX or DOX-LIP was examined. Results showed a strong synergistic effect of CAP and DOX or DOX-LIP on selectively decreasing cell viability of melanoma cells. CAP accelerated the apoptotic effect of DOX (or DOX-LIP) and dramatically reduced the aggressiveness of melanoma cells, as the combination treatment significantly decreased their anchorage independent growth. Moreover, CAP did not result in increased cellular uptake of DOX under the present experimental conditions. In conclusion, CAP facilitates DOX cytotoxic effects on melanoma cells, and affects their metastatic potential by reducing their clonogenicity, as shown for the first time.

Indexed as

AnimalsCell Line, TumorCell ProliferationCell SurvivalDoxorubicinDrug SynergismHumansMelanomaMicePlasma GasesPolyethylene GlycolsDoxorubicinliposomal doxorubicinPlasma GasesPolyethylene Glycols

Identifiers

PMID34285268
PMCPMC8292331
OpenAlexW3184552990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.